
Sign up to save your podcasts
Or
Dave discussed the latest update in the OFA vs FDA compound tirzepatide battle, as well as this weeks news in obesity medicine.
Find our substack and all promotional links here:
4.9
231231 ratings
Dave discussed the latest update in the OFA vs FDA compound tirzepatide battle, as well as this weeks news in obesity medicine.
Find our substack and all promotional links here:
1,204 Listeners
333 Listeners
36 Listeners
59 Listeners
505 Listeners
270 Listeners
1,593 Listeners
379 Listeners
71 Listeners
56 Listeners
199 Listeners
180 Listeners
20 Listeners
99 Listeners
28 Listeners